therapeut
grobi
road
hospit
leicest
remain
two
articl
seri
concentr
clinic
applic
antivir
agent
man
guidelin
treatment
offer
end
section
viral
group
viral
upperrespiratorytract
infect
remain
lead
caus
acut
morbid
econom
loss
throughout
world
coryza
relat
symptom
caus
multitud
virus
serotyp
ofwhich
antigen
unstabl
uncontrol
vaccin
common
cold
influenza
long
major
target
antivir
chemotherapi
section
summaris
data
concern
influenza
b
rhino
corona
respiratori
syncyti
viru
rsv
infect
antivir
distinct
limit
efficaci
amantadin
structur
relat
compound
rimantadin
effect
prevent
ill
caus
h
nl
subtyp
influenza
influenza
b
natur
acquir
experiment
induc
man
prophylact
efficaci
report
chronic
sick
elderli
peopl
includ
children
well
healthi
evid
control
studi
mani
thousand
peopl
amantadin
rimantadin
effect
prevent
infect
effect
prevent
amelior
ill
distinct
may
desir
featur
prophylaxi
sinc
subclin
infect
could
confer
immun
reinfect
concern
sideeffect
cast
doubt
use
amantadin
rimantadin
outbreak
influenza
attackr
prevent
amelior
ill
amantadin
accomplish
expens
minor
centralnervoussystem
sideeffect
number
rimantadin
far
better
toler
respect
even
treatment
either
drug
best
restrict
peopl
high
risk
infect
consequ
influenza
local
possibl
candid
would
unvaccin
children
adult
high
risk
underli
diseas
unvaccin
adult
essenti
commun
posit
household
contact
index
case
peopl
unabl
receiv
influenza
vaccin
egg
sensit
peopl
live
semiclos
institut
ussr
intranas
administr
lowtitr
interferonalpha
report
prevent
influenza
result
yet
substanti
oral
inosiplex
isoprinosin
molar
complex
inosin
dimethylaminoisopropanolpacetamidobenzo
immunopotenti
oral
ribavirin
evalu
man
sideeffect
yield
inconsist
result
oral
treatment
amantadin
rimantadin
start
within
first
hour
symptom
cut
durat
fever
effect
influenza
daysi
shorten
ill
roughli
onethird
reduct
influenz
symptom
far
outweigh
toxic
effect
addit
agent
may
reduc
durat
amount
viral
shed
oral
amantadin
acceler
resolut
peripher
airway
abnorm
accompani
influenza
date
control
studi
therapeut
effect
amantadin
primari
influenza
pneumonia
peopl
treat
mg
day
seem
benefit
amantadin
wide
prescrib
reason
includ
unfamiliar
drug
antivir
effect
delay
medic
consult
concern
patient
respiratori
infect
influenza
might
treat
place
unnecessari
risk
toxic
effect
known
influenza
outbreak
howev
almost
individu
acut
onset
feverish
cough
headach
myalgia
anorexia
without
vomit
diarrhoea
influenza
ought
consid
treatment
hour
onset
symptom
prospect
benefit
diminish
amantadin
rimantadin
ribavirin
given
aerosol
hope
provid
high
concentr
drug
throughout
airway
minimum
toxic
compar
placebo
amantadin
aerosol
gldl
given
minut
three
time
day
day
acceler
recoveri
natur
acquir
influenza
viru
infect
howev
caus
mild
local
sideeffect
inconveni
administ
seem
effect
oral
administ
drug
similar
result
obtain
rimantadin
aerosol
experiment
influenza
infect
ribavirin
broader
spectrum
antivir
activ
includ
influenza
b
rsv
either
amantadin
rimantadin
result
oral
treatment
inconsist
given
aerosol
within
first
h
symptom
influenza
g
drug
h
day
ribavirin
acceler
resolut
fever
ill
reduc
viru
improv
best
modest
certainli
insuffici
justifi
treatment
otherwis
healthi
subject
influenza
b
ribavirin
smallparticl
aerosol
yield
result
similar
influenza
date
benefit
seen
patient
symptom
less
hour
durat
receiv
h
treatment
total
respiratori
syncyti
viru
treatment
therapeut
efficaci
ribavirin
aerosol
evalu
adult
infect
rsv
experiment
infant
infect
natur
adult
volunt
ribavirin
placebo
start
day
intranas
inocul
rsv
given
total
h
day
ribavirin
effect
minor
upperrespiratorytract
symptom
rhiniti
sore
throat
sneez
lymphadenopathi
reduc
system
complaint
cough
fever
drug
evalu
doubleblind
control
trial
children
age
week
year
hospit
rsv
treatment
initi
mean
day
onset
symptom
drug
placebo
administ
almost
continu
day
infant
oxygen
hood
oxygen
tent
inhal
tube
respir
estim
dosag
mgkg
bodyweight
per
hour
end
treatment
infant
receiv
ribavirin
significantli
greater
improv
cough
rale
intercost
muscl
retract
lethargi
arteri
oxygen
satur
viral
shed
wherea
temperatur
nasal
congest
rhinorrhoea
wheez
unaffect
anoth
studi
daili
treatment
day
associ
rapid
resolut
bronchiol
trend
toward
rapid
improv
rhiniti
nasal
discharg
obstruct
studi
toxic
sideeffect
note
ribavirin
remain
investig
good
case
use
certain
infant
rsv
infect
first
month
lifefor
exampl
admit
hospit
congenit
heart
diseas
sever
combin
immunodefici
diseas
rhinoviru
prophylaxi
merigan
et
show
partli
purifi
interferonalpha
given
frequent
nasal
spray
day
could
reduc
symptom
viru
shed
result
experiment
infect
rhinoviru
type
second
day
sever
group
confirm
efficaci
prevent
amelior
ill
influenc
infect
rate
vari
sinc
subclin
infect
could
confer
immun
reinfect
high
infect
rate
mean
disappoint
main
drawback
quantiti
necessari
benefici
effect
intranas
interferon
may
caus
local
complic
longterm
use
inappropri
prophylaxi
minor
ill
instead
could
given
short
period
close
contact
index
case
inde
preliminari
data
indic
approach
may
safe
effect
prophylact
effect
interferonbeta
littl
studi
date
one
experi
ml
uml
given
nostril
time
daili
day
rhinoviru
challeng
second
day
reduct
symptom
viral
scarciti
interferon
past
prompt
sever
clinic
trial
interferon
induc
trial
topic
appli
polyinosinicpolycytidil
acid
synthet
doublestrand
rna
point
reduct
symptom
volunt
infect
agent
probabl
toxic
use
acut
selflimit
condit
investig
agent
propanediamin
call
seem
nontox
consist
reduc
symptom
rhinoviru
infect
administ
nasal
spray
three
four
time
daili
day
viru
challeng
howev
doubleblind
placebocontrol
studi
ineffect
prevent
cold
given
daili
altern
approach
use
specif
antivir
far
yield
encourag
result
enviroxim
potent
inhibitor
rhinoviru
replic
vitro
evalu
clinic
unit
state
britain
although
prophylact
administr
drug
associ
reduct
certain
symptom
clinic
score
treatment
placebo
group
differ
significantli
drug
prevent
infect
variou
compound
includ
propanediamin
interferoninduc
treatment
infect
due
rhinoviru
vitamin
c
common
cold
far
yield
disappoint
result
anecdot
evid
ribavirin
aerosol
use
lifethreaten
parainfluenzaviru
infect
gelfand
et
treat
infant
sever
combin
immunodefici
respiratori
distress
associ
isol
parainfluenzaviru
type
end
first
cours
afebril
respiratori
prophylact
effect
interferonalpha
investig
volunt
experiment
infect
strain
coronaviru
administ
intranas
spray
three
time
daili
coronaviru
challeng
second
day
treatment
compar
placebo
interferonalpha
significantli
reduc
number
cold
viru
shed
also
diminish
studi
rhinoviru
subclin
infect
common
interferon
recipi
thu
allow
subject
acquir
natur
immun
guidelin
summaris
tabl
genit
infect
herp
simplex
viru
commonli
hsv
type
major
caus
genit
ulcer
worldwid
britain
number
genit
herp
simplex
infect
increas
per
annum
recent
year
case
report
sexuallytransmitteddiseas
clinic
unit
state
number
may
high
primari
case
million
recurr
year
primari
lesion
may
persist
sever
week
pain
complic
urinari
retent
centralnervoussystem
manifest
requir
admiss
hospit
recurr
tend
shorter
durat
less
sever
though
still
caus
consider
morbid
also
associ
neonat
infect
repres
hazard
new
sexual
contact
topic
oral
intraven
prepar
acyclovir
acv
benefici
effect
viru
shed
heal
gener
improv
pain
symptom
topic
acvtreat
acv
cream
propylen
glycol
base
appli
time
daili
day
evalu
patient
first
episod
genit
herp
less
day
reduc
median
durat
pain
day
time
complet
heal
day
viru
shed
day
women
durat
dysuria
shorten
day
multicentr
trial
acv
ointment
polyethylen
glycol
base
compar
placebo
treatment
start
within
day
onset
lesion
appli
time
daili
patient
treat
acv
mean
durat
viral
shed
reduc
day
durat
pain
time
complet
heal
also
shorten
sever
day
differ
acv
placebo
group
consist
signific
topic
acv
ointment
effect
system
sequela
fever
headach
photophobia
neck
stiff
dysuria
vagin
cf
mdash
treatment
oral
acv
mg
five
time
daili
day
similarli
investig
patient
initi
episod
genit
herp
less
day
durat
among
acv
recipi
mean
durat
viral
shed
reduc
day
pain
gener
reduc
complet
heal
acceler
mean
durat
dysuria
tender
adenopathi
lessen
day
respect
intraven
acvintraven
acv
mgkg
bodyweight
day
also
evalu
patient
first
attack
genit
herp
less
day
reduc
median
durat
viral
shed
day
consist
effect
durat
pain
time
complet
heal
vagin
discharg
dysuria
sore
throat
system
complaint
significantli
reduc
drug
sinc
intraven
oral
acv
efficaci
intraven
therapi
reserv
hospit
patient
unfortun
acv
treatment
primari
genit
herp
affect
recurr
rate
topic
oral
prepar
acv
evalu
recurr
genit
herp
topic
acvtop
acv
ointment
given
four
six
time
daili
day
treatment
initi
within
h
onset
symptom
shorten
viral
shed
day
pain
littl
affect
essenti
benefici
effect
treatment
acv
cream
appli
time
daili
day
investig
patient
recurr
less
hour
durat
reduc
median
durat
pain
day
combin
symptom
oral
acvor
acv
mg
five
time
daili
day
similarli
evalu
patient
recurr
episod
less
hour
durat
one
patient
began
treatment
mean
h
first
sign
symptom
recurr
among
acv
recipi
mean
durat
viral
shed
reduc
day
durat
pain
unaffect
even
patientinitiatedtherapi
group
time
complet
heal
reduc
day
longterm
prophylaxi
acv
investig
mean
prevent
frequent
debilit
recurr
strau
et
conduct
trial
oral
acv
mg
time
daili
day
time
daili
placebo
patient
evalu
took
prepar
day
drug
well
toler
significantli
fewer
recurr
acv
recipi
placebo
recipi
incid
virolog
confirm
recurr
versu
dougla
et
record
incid
day
placebo
recipi
compar
patient
receiv
mg
time
day
receiv
mg
twice
day
british
mg
time
day
week
reduc
recurr
rate
placebo
recipi
strau
et
al
isol
drugresist
virus
patient
receiv
acv
recurr
patient
associ
drugsensit
virus
place
prophylaxi
acv
remain
uncertain
especi
view
scarciti
data
longterm
safeti
develop
resist
nevertheless
agent
seem
highli
benefici
patient
frequent
recurr
could
enorm
valu
prevent
spread
infect
present
reserv
severest
case
besid
acv
numer
therapi
evalu
year
mostli
proven
ineffect
inadequ
assess
initi
studi
topic
surfact
ether
nonoxynol
photodynam
inactiv
proflavin
neutral
red
suggest
antivir
effect
placebo
control
studi
show
none
clinic
activ
control
investig
topic
appli
idoxuridin
idu
one
show
ointment
ineffect
anoth
suggest
idu
dimethylsulphoxid
dmso
shorten
viral
shed
aid
anoth
show
clinic
benefit
idu
dmso
either
primari
recurr
topic
administ
vidarabin
cream
seem
equal
ineffect
treatment
oral
ribavirin
mg
daili
day
reportedli
reduc
sever
pain
new
lesion
format
result
await
confirm
similarli
topic
inhibitor
envelop
protein
glycosyl
said
acceler
recoveri
initi
infect
reduc
frequenc
sever
recurr
episod
genit
though
agent
therapeut
efficaci
anim
model
infect
guidelin
summaris
tabl
ii
herpet
kerat
ocular
hsv
infect
caus
usual
lead
communic
caus
blind
develop
countri
primari
ocular
infect
acquir
earli
life
caus
vesicl
lid
follicular
blepharoconjunct
mani
instanc
initi
infect
subclin
recurr
viral
replic
initi
produc
small
vesicular
lesion
corneal
epitheli
cell
may
ruptur
coalesc
form
dendrit
amoeboid
ulcer
result
disabl
pain
condit
may
eventu
progress
deep
stromal
kerat
necrosi
vascularis
scar
recurr
ocular
herp
tend
sever
primari
infect
aris
patient
within
year
initi
episod
within
year
second
attack
fortun
sever
drug
establish
efficaci
treatment
ocular
herp
topic
appli
idu
use
sinc
treatment
herpet
kerat
averag
cure
rate
cure
rate
primari
recurr
case
ident
favour
result
commonli
achiev
first
day
toxic
sideeffect
infrequ
howev
poor
ocular
penetr
make
less
satisfactori
deep
infect
idu
longer
drug
first
choic
vidarabin
anoth
poorli
solubl
compound
becam
second
antivir
wide
use
treatment
ocular
herp
evid
numer
studi
effect
idu
herpet
kerat
one
doubleblind
trial
compar
two
treatment
failur
record
idutr
patient
vidarabinetr
patient
mean
time
heal
day
either
vidarabin
coupl
corticosteroid
therapi
also
seem
benefici
stromal
despit
poor
solubl
nonpenetr
healthi
human
toxic
reaction
similar
caus
idu
develop
patient
despit
efficaci
mani
clinician
favour
acyclovir
initi
manag
ocular
herp
trifluorothymidin
clinic
use
decad
market
european
countri
uk
usa
approv
treatment
ocular
herp
topic
appli
prove
consist
effect
idu
averag
cure
rate
dendrit
geograph
corneal
lesion
deg
heal
time
also
consist
shorter
sever
day
also
better
vidarabin
treatment
amoeboid
ulcer
dendrit
geograph
ulcer
though
trend
toward
superior
effect
also
treatment
kerat
unrespons
idu
vidarabin
prefer
either
agent
larg
ulcer
complic
diseas
advers
reaction
similar
idu
seem
less
common
sinc
report
crosstox
ocular
antivir
drug
use
reaction
agent
sinc
crossresist
antivir
altern
agent
confid
substitut
clinic
improv
within
day
circumst
howev
possibl
caus
delay
heal
excludedfor
exampl
insuffici
drug
applic
underli
stromal
reaction
topic
acv
thoroughli
evalu
clinic
shown
least
effect
idu
vidarabin
treatment
herp
kerat
possibl
superior
patient
dendrit
geograph
corneal
lesion
heal
acv
rate
heal
acv
recipi
seem
distinctli
faster
antiviralsaverag
heal
time
day
uncontrol
trial
ophthalm
prepar
ofbromovinyldeoxyuridin
yield
promis
result
herp
simplex
kerat
maugdal
et
agent
patient
mani
unrespons
idu
vidarabin
patient
respond
favour
averag
heal
time
day
dendrit
ulcer
day
geograph
lesion
sign
toxic
hypersensit
note
patient
topic
applic
interferonalpha
extens
investig
dendrit
kerat
mostli
disappoint
result
exogen
interferon
alon
suffici
effect
must
use
conjunct
either
debrid
anoth
antivir
sundmach
et
report
coadministr
interferon
x
uml
gave
significantli
faster
heal
alon
scope
improv
treatment
hsv
kerat
guidelin
summaris
tabl
iii
